



ASX ANNOUNCEMENT

PRRS vaccine trial preliminary results

- *Lead vaccine candidate chosen for further trials*
- *Lab work to add new components to vaccine nearing completion*
- *International animal health company interest in PRRS vaccine increases*

18 October 2007, Sydney, Australia: Trials to evaluate Imugene's PRRS vaccine have been completed at a specialist trial facility in the US. The trial aimed to determine the best of three PAV based vaccine candidates for progression in the development program. Preliminary results have been received and the best performing candidate from the trial has been chosen to proceed in the product development program. Further detailed results from post trial blood testing and analysis should be received this quarter and will assist design of the next trial.

The trials are part of Imugene's vaccine product development and follows successful previous trials of the PRRS vaccine in Australia. The current trial measured reductions in the PRRS virus load in the blood of PRRS challenged pigs for three weeks following infection as an important indicator of efficacy.

Imugene managing director Dr Warwick Lamb said, "Laboratory work is nearing completion on a final modification to the vaccine. Recent external scientific information indicated that by modifying part of the existing vaccine and adding an additional component the result may be a significant improvement in vaccine efficacy. These changes involve genetic engineering and are ideally suited to the vector based system of vaccine production. We commenced work on these modifications in July this year and we hope the completed candidates will enter the next animal trial early in 2008."

Imugene is continuing discussions with interested major international animal health companies with a view to possible licensing agreements.

PRRS is one of the most economically damaging pig diseases worldwide causing industry losses of up to \$1 billion each year. Initially recognised in the US in 1987 the disease spread to Europe in 1990 and subsequently across most of the rest of the world. Australia is one of three countries considered PRRS-free.

The vaccine is based on Imugene's Porcine Adenoviral Delivery Vector that delivers selected genetic material to the pig to stimulate the immune system to protect against the PRRS virus.

Perth Office

Level 20, Allendale Square
77 St Georges Terrace
Perth WA 6000
Tel: +61 8 9440 2660
Fax: +61 8 9440 2699

ABN: 99 009 179 551

Sydney Office

Registered Office
Level 1, 14 – 20 Delhi Road
North Ryde NSW 2113
Tel: +61 2 9870 7330
Fax: +61 2 9888 9338

www.imugene.com

ENDS

About Imugene

Imugene specialises in commercialising animal health products for production animals including pigs and poultry.

Imugene owns the worldwide rights to the Fowl Adenoviral Vector Delivery System for poultry and the Porcine Adenoviral Vector Delivery System for pigs. Imugene has successfully licensed the first product based on the Fowl Adenoviral Vector Delivery System – the Poultry Productivity Enhancer.

Imugene's poultry and pig portfolio is targeting a worldwide US\$3 billion annual market with four lead vaccine products under development and a strong product pipeline. Consumer demands for disease free and residue free food will bolster Imugene's prospects.

Imugene's products safely prevent disease and reduce or eliminate antibiotics and harmful chemicals in animals. Animal antibiotics and chemicals in the human food chain have been linked to the emergence of dangerous resistant bacteria in people and food residues.

For more information please visit the Imugene Website www.imugene.com

For more information:

Dr Warwick Lamb	Mr Graham Dowland	Mr Rudi Michelson
Managing Director	Executive Chairman	Monsoon Communications
+61 2 9870 7330	+61 8 9440 2660	+61 3 9620 3333